?IMT504 inhibits insulitis and lowers blood glucose in nod/ltj female mice in a short-term treatment.?

BIANCHI MARIA SILVIA; LUX-LANTOS VICTORIA; LIBERTUN C; BIANCHI S

Congreso; Reunion Conjunta de Sociedades de Biociencia, Sociedad Argetina de Biologia (SAB), Buenos Aires, Argentina.; 2017

IMT504 INHIBITS INSULITIS AND LOWERS BLOOD GLUCOSE IN NOD/Ltj FEMALE MICE IN A SHORT-TERM TREATMENT Immunomodulatory oligonucleotide IMT504 (IMT) induced a marked recovery of glycemia, glucose clearence, insulin secretion and beta cell function (by HOMA beta cell index) on a spontaneous autoimmune diabetes model (in male and female NOD/Ltj mice).We analyzed the minimun dose at which the IMT has an early effect on glycemic control and insulitis. Diabetic female NOD/LtJ mice (two consecutive non-fasted glycemia (Gly) levels ≥ 250 mg/dl) were treated with a daily dose of IMT for five days (IMT: 2, 6 or 20 mg/kg/day, IMT2, IMT6 and IMT20) or saline as control (DC). Mice were sacrificed the day following the last injection. In fasted conditions, blood samples and pancreases were obtained for Gly and insulinemia measurment and for histological studies respectively.We observed that 12.5% (1/8) DC mice showed spontaneous reversion of diabetic condition, whereas IMT improved Gly in 62.5% (5/8), 50% (4/8) and 75% (6/8) of mice treated with 2, 6 and 20 mg/kg/day, respectively (X2: DC vs IMT20: p